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Among all the parasitic diseases that beset human beings in the tropical parts of the
world, malaria is still the major cause of morbidity and mortality (1). Primaquine (PQ) is
the only currently available drug that is active against both the latent liver forms of re-
lapsing malaria caused by Plasmodium vivax and Plasmodium ovale and the gametocytes
from all parasite species causing human malaria, including chloroquine-resistant Plas-
modium falciparum. Its usefulness is, however, offset by its inherent toxicity and rapid bio-
transformation to carboxyprimaquine, which is devoid of significant antimalarial activ-
ity (2). Many attempts have been made to synthesize and evaluate analogues of prima-
quine in the search for compounds that would be more effective or less toxic. Several
authors have shown that attachment of an amino acid or peptide residue to the primary
amino group protected primaquine against the aforementioned metabolic process and
led to a substantial increase in antimalarial activities (3, 4). Despite the improved activ-
ity/toxicity ratio, most of these derivatives are rapidly hydrolyzed to primaquine by ami-
nopeptidases and endopeptidases (5). Pharmacological activity of primaquine in vivo
was significantly improved when this drug was covalently coupled to lysosomotropic
drug carriers – polyacryl starch microparticles (6) or asialofetuin (7) via tri-, tetra-, and
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pentapeptide spacers. Having these observations in mind, we have prepared primaquine
conjugates, in which primaquine is covalently bound to a hydrophilic polyamino acid.
Two polymers of polyaspartamide type, poly[a,b-(N-2-hydroxyethyl-DL-aspartamide)]
(PHEA) and poly[a,b-(N-3-hydroxypropyl-DL-aspartamide)] (PHPA), were chosen as mo-
del carriers in polymer-drug conjugates. In this paper, we report the synthesis, charac-
terization and preliminary antimalarial evaluations of the novel primaquine polymeric
conjugates, along with a low-molecular-mass glucosamine conjugate. Conjugation of drugs
to polymeric carriers to form macromolecular prodrugs might be a useful approach to
improve drug solubility, stability and prolong drug release, reduce doses, dosing inter-
vals and drug toxicity or to achieve targetability (8, 9). Other delivery systems described
in literature include an ethyl cellulose-based transdermal therapeutic system (10), colloi-
dal carriers liposomes, polymeric and lipid nanoparticles (11) and artificial chylomicron
emulsion (12).
EXPERIMENTAL
Chemistry
Materials and general methods. – Melting points were determined on a Stuart Melting
Point Apparatus SMP3 (Barworld Scientific, UK) and were uncorrected. IR spectra were
recorded on a FTIR Perkin Elmer Paragon 500 spectrometer (Perkin Elmer, USA). 1H and
13C NMR spectra were recorded on a Varian Gemini 300 spectrometer, operating at 300
and 75.5 MHz for the 1H and 13C nuclei, respectively (Varian, UK). Samples were mea-
sured in DMSO-d6 solutions at 20 °C in 5 mm NMR tubes. Chemical shifts (d) in ppm
were referred to tetramethylsilane (TMS). UV spectra were recorded on a Shimadzu UV
1601 spectrometer (Shimadzu Co., Japan). Dialysis was performed using cellulose dialy-
sis tubings with a molecular mass cut-off 8,000–15,000 (Serva, Germany). Precoated Merck
silica gel 60 F254 plates (Merck, Germany) and solvent systems cyclohexane/ethyl ace-
tate/methanol (3:1:1.5 or 3:1:0.25) were used for thin-layer chromatography. Spots were
visualized by short-wave UV light and iodine vapour. Primaquine diphosphate, gluco-
samine hydrochloride, L-aspartic acid, 2-hydroxyethylamine, 3-hydroxypropylamine and
triethylamine (TEA) were purchased from Aldrich (USA). Compounds 1-4 were prepa-
red according to the published procedures (13-15).
Primaquine benzotriazolide (PQ-Bt, 2). – Compound 2 was prepared by acylation of
primaquine base with chloride 1 (13). Primaquine base was prepared from primaquine
diphosphate, keeping the drug solution light protected.
Poly[a,b-(N-2-hydroxyethyl-DL-aspartamide)] (PHEA, 3). – Polymer 3 was prepared by
aminolysis of poly-DL-(2,5-dioxo-1,3-pyrrolidinediyl (PSI) with 2-hydroxyethylamine.
PSI was prepared by thermal polycondenzation of L-aspartic acid. Average molecular
mass of PHEA was 60,000 (14).
Poly[a,b-(N-3-hydroxypropyl-DL-aspartamide)] (PHPA, 4). – Polymer 4 was prepared by
aminolysis of poly-DL-(2,5-dioxo-1,3-pyrrolidinediyl (PSI) with 3-hydroxypropylamine
(15).
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Primaquine-glucosamine conjugate [1-(4-(6-methoxyquinolin-8-ylamino)pentyl)-3-((tetra-
hydro-2,4,5-trihydroxy-6-(hydroxymethyl)-2H-pyran-3-yl)methyl)urea] (PQ-G, 5). – A mixture
of 0.209 g (0.50 mmol) primaquine benzotriazolide 2, 0.170 g (0.75 mmol) glucosamine
hydrochloride and 0.101 g (1.00 mmol) TEA in 6 mL absolute ethanol was stirred at room
temperature for 4 days, light protected. Dry ether (20 mL) was added and the precipi-
tated product 5 was filtered off and triturated with ether several times [yield: 0.203 g (59
%); m.p. 122–126 °C; IR (KBr): nmax 3415, 3294, 3098, 3041, 2943, 2883, 1617, 1582, 1538,
1456, 1422, 1390, 1094, 1063, 1034, 611 cm–1; 1H NMR (DMSO-d6), d (ppm): 8.53–8.51 (d,
1H, 16), 8.06–8.02 (d, 1H, 14), 7.44–7.40 (m, 1H, 15), 7.17–7.15 (d, 1H, 7’), 6.47 (s, 1H, 9),
6.42–6.41 (d, 1H, 7), 6.26 (s, 1H, 11), 6.12 (t, 1H, 1), 6.10 (d, 1H, 2’), 5.66–5.64 (d, 1H, 4’),
5.56–5.58 (d, 1H, 5’), 5.26 (q, 1H, 6’), 5.24 (t, 1H, 3’), 4.91–4.86 (t, 2H, 8’), 4.65 (s, 1H, OH),
4.52 (s, 1H, OH), 4.39 (s, 1H, OH), 3.82 (s, 3H, 17), 3.69–3.62 (m, 2H, CH-5, OH), 3.00–2.83
(q, 2H, 2), 1.54–1.41 (m, 4H, 3, 4), 1.19 (s, 3H, 6); 13C NMR (DMSO-d6), d (ppm): 158.97
(10), 158.19 (1’), 144.61 (8), 144.23 (16), 134.77 (14), 134.48 (13), 129.54 (12), 122.07 (15),
96.08 (9), 91.62, 91.25 (7’), 88.93 (11), 71.65, 71.21 (6’), 70.80, 70.23 (4’), 69.84, 69.82 (5’),
61.15, 61.05 (8’), 54.96 (17), 54.59, 54.46 (3’), 47.04 (5), 40,76 (2), 33.54 (4), 26.87 (3), 20.22
(6) (atom enumeration is presented in Fig. 1); elemental analysis for C22H33N4O7 (465.52)
(%): calcd. C 56.76, H 7.15, N 12.04; found: C 56.35, H 7.08, N 12.40].
Poly[a,b-(N-2-hydroxyethyl-DL-aspartamide)]-primaquine conjugate (PHEA-PQ) (6). – a)
A solution of 0.244 g (0.603 mmol) primaquine benzotriazolide (2), 0.191 g (1.206 mmol)
PHEA (3) (calculated as a monomer unit) and 0.122 g (1.206 mmol) TEA in 12 mL of dry
N,N’-dimethylformamide (DMF) was stirred at room temperature for 5 days. The sol-
vent was evaporated under reduced pressure and the residue was triturated with ace-
tone and ether until pure product 6a was obtained [yield: 0.100 g (24 %); IR (KBr): nmax
3308, 3080, 2938, 2880, 1652, 1520, 1424, 1386, 1221, 1167, 1137, 1057, 899, 880, 823, 791,
672, 625, 532 cm–1; UV (ethanol/water 2.5:1): lmax 266 nm (A = 0.541, g = 32 mg mL–1);
drug loading: 19.5 %].
b) A solution of 0.300 g (0.741 mmol) primaquine benzotriazolide (2), 0.190 g (1.482
mmol) PHEA (3) and 0.299 g (2.964 mmol) TEA in 10 mL of dry DMF was heated at 60
°C for 14 h. The solvent was evaporated under reduced pressure and the residue was
triturated with acetone and ether until pure product 6b was obtained [yield: 0.264 g (47
%); UV (ethanol/water 2.5:1): lmax 266 nm (A = 0.673, g = 30.2 mg mL–1); drug loading:
26 %].
Poly[a,b-(N-3-hydroxypropyl-DL-aspartamide)]-primaquine conjugate (PHPA-PQ) (7). –
A solution of 0.300 g (0.741 mmol) primaquine benzotriazolide (2), 0.255 g (1.481 mmol)
PHPA (4) (calculated as a monomer unit) and 0.299 g (2.961 mmol) TEA in 10 mL of dry
DMF was heated at 60 °C for 4 h. The solvent was evaporated under reduced pressure
and the residue was triturated with acetone and ether until pure product 7 was obtained
[yield: 0.246 g (46 %); IR (KBr) nmax 3298, 3084, 2941, 2880, 1652, 1540, 1523, 1424, 1386,
1261, 1201, 1169, 1134, 1052, 1000, 967, 823, 791, 668 cm–1; UV (ethanol/water 2.5:1): lmax
266 nm (A = 0.712, g = 45.2 mg mL–1); drug loading: 14.6 %].
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Pharmacological evaluation
Animals. – Swiss mice (15–20 g) of both sexes were obtained from the Central Ani-
mal Facility of the National Institute of Pharmaceutical Education and Research, S.A.S.
Nagar, India. Mice were randomly distributed into groups and housed in cages (6 per
cage) and maintained under standard conditions at 26 ± 2 °C and 44–56 % relative hu-
midity, and 10 h light 14 h dark cycles each day for one week before and during the ex-
periments. All animals were fed the standard rodent diet (Amrut, India) and were pro-
vided clean water containing 0.05 % p-amino benzoic acid, ad libitum. All studies were
performed in accordance with the guidelines for the care and use of laboratory animals,
after obtaining the Institutional Animal Ethics Committee Approval.
Antimalarial screening. – The synthesized compounds were tested for their potential
blood-schizontocidal activity against a sensitive strain of the rodent malaria parasite Plas-
modium berghei KSP11, which is maintained in the laboratory by both cryopreservation
and animal passage. Mice, six per group, were infected, intraperitoneally, with a stan-
dard inoculum of 1 ´ 107 infected-erythrocytes (IE; mainly rings) from previously infec-
ted (nearly 5 % parasitaemia) donor mice. In each experiment, two hours after initiation
of infection, mice in the test groups were administered graded four equal doses of the
test compounds homogenously suspended or dissolved in water (vehicle), orally, on day
+ 0, day + 1, day + 2 and day + 3; a group of negative control (vehicle only) and a group
of positive control (chloroquine diphosphate; 8 mg kg–1 per day 4 days) mice were in-
variably included. For the determination of parasitaemia on day + 4 and day + 7, tail-
-blood thin smears were prepared, stained with Giemsa and examined under the oil-im-
mersion lens of a light microscope. The minimum dose of test compounds that suppressed
the infection on both day + 4 and day + 7 was marked as minimum effective dose (MED),
and the MED that could completely eliminate parasitaemia as assessed by the absence of
parasites in the smears up to day + 60 was designated as minimum curative dose. A
compound was considered inactive if at a particular dose it could not suppress the para-
sitaemia either on day + 4 or on day + 7 or on both of these days, and the animals died
of infection like in the negative control. At 8 mg kg–1 per day chloroquine for 4 days, all
the positive control mice were slide negative on both day + 4 and day + 7.
Statistical significance was determined using the SigmaStat 2.03 software (Student-
-Newman-Kelus method).
RESULTS AND DISCUSSION
Chemistry
Novel primaquine conjugates with glucosamine and two polyaspartamides, PHEA
and PHPA, were prepared. Conjugation with glucosamine was performed in order to
obtain a low-molecular-mass water soluble conjugate. Glucosamine primaquine conju-
gate (PQ-G, 5) was synthesized by aminolysis of primaquine benzotriazolide 2 with glu-
cosamine, following our previously published method for primaquine ureas (13). Com-
pound 2 was prepared by acylation of primaquine base with 1-benzotriazole carboxylic
acid chloride (BtcCl, 1) (Scheme 1). Conjugate 5 is fairly soluble in water and well solu-
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ble in the ethanol/water (2.5:1) mixture. IR spectrum shows absorptions at 3415 (OH),
3294 (NH) and three typical urea carbonyl absorptions at 1617, 1582 and 1538 cm–1.
1H NMR spectrum of the primaquine conjugate reveals pyridine hydrogens at 8.53 and
7.40 ppm, benzene hydrogens between 6.47 and 6.26 ppm, three NH groups (at 6.42, 6.12
and 6.10 ppm), glucosamine hydrogens between 5.66 and 4.39 ppm, hydroxyl at anomeric
C-atom at 7.17–7.15 ppm and methoxy group at 3.82 ppm. A new urea carbonyl at 158.19
and absorptions between 91 and 54 ppm of the glucosamine moiety are present in the
13C NMR spectrum, in addition to C-atoms of primaquine residue. Fig. 1 represents the
chemical structure of compound 5 and atom enumeration.
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Benzotriazolide 2 was a convenient starting compound for the preparation of poly-
mer-drug conjugates as well (Scheme 1). Two polymers of polyaspartamide type, PHEA
(3) and PHPA (4), were chosen as model carriers in polymer-drug conjugates because of
their physiological acceptance and excellent physicochemical characteristics such as high
aqueous solubility, low toxicity (16), abundant hydroxyl groups for drug conjugation and
availability in a wide range of molecular masses. The starting polymers PHEA and PHPA
were prepared by aminolysis of poly-DL-(2,5-dioxo-1,3-pyrrolidinediyl) (PSI) with 2-hy-
droxyethylamine and 3-hydroxypropylamine, respectively, while PSI was prepared by
thermal polycondensation of L-aspartic acid (14, 15). The reaction between 2 and PHEA/
PHPA was performed in a DMF solution, in a molar ratio 1:2 (calculated as monomer
units). The following polymer-drug conjugates were prepared: PHEA-PQ (6a), PHEA-
-PQ (6b) and PHPA-PQ (7). In these conjugates, primaquine is bound to hydroxyl bear-
ing polymeric carriers by cleavable carbamate bonds. The synthesized conjugates diffe-
red in their spacer length and drug loading.
Drug-loading in polymer-drug conjugates was estimated by UV-spectroscopy at l =
266 nm using the calibration line for primaquine (A = 80.725; g + 0.0372, R = 0.9997). Per-
centage of primaquine ranged from 14.6 to 26 %. Drug-loading in the conjugates was not
strictly stoichiometric. The experimentally determined drug-loading was lower than the
expected loading due to incomplete coupling reactions (the molar ratio of reactant 2 and
monomer units of PHEA or PHPA 1:1 enabled binding of the drug to half of the hydro-
xyl groups available). Drug loading was higher if the reaction was performed at higher
temperature. No substituted hydroxyl groups assured hydrosolubility of the conjugates.
The proof that primaquine was covalently bound in the prepared polymer-drug
conjugates was found in the UV-spectra. The conjugates absorbed UV-light in the same
absorption ranges as primaquine, whereas PHEA and PHPA had no UV-absorption at
these wavelengths. The absence of nonconjugated drug was confirmed by TLC using
solvent systems in which polymer derivatives remained at the start and primaquine and
benzotriazolide 2 moved with the mobile phase. In the IR spectra of conjugates 6a,b and
7, strong amide carbonyl absorptions at 1652 (amide I) and 1540 cm–1 (amide II) are
present, similarly to PHEA and PHPA. Carbamate absorption overlaps with these ab-
sorptions, while new absorptions coming from aromatic primaquine moieties are visible
at 3080, 823 and 792 cm–1.
Biological results
One primaquine glucosamine conjugate (5) and three polymeric conjugates (6a,b and
7) were tested for their blood-schizontocidal activity against the rodent malaria parasite
Plasmodium berghei infection in mice (Table I). The compounds were administered from
day 0–3 post-infection, orally. Except for compound 6a, which was tested at 75 mg kg–1
per day for 4 days, all the remaining compounds were tested at 150 mg kg–1 per day for
4 days. For the assessment of the potential blood-schizontocidal activity of the test com-
pounds, parasitaemia in treated mice on day + 4 and day + 7 was compared with those
of the negative-control and positive-control mice on the same days. Mice in the nega-
tive-control group were administered vehicle only, and all of these mice became patent
on day + 2, showed 5.6 ± 1.0 % and 16.8 ± 4.3 % parasitaemia on day + 4 and day + 7, re-
spectively, and finally died of up to 75 % infection between day + 10 and day + 14 post
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infection. Positive-control group mice were administered chloroquine (8 mg kg-1 per day,
4 days); these mice did not show any patent parasitaemia on either day + 4 or day + 7.
Compared to the negative controls, mice treated with compound 5 showed signifi-
cantly (p < 0.001) lower parasitaemia; however, all these mice died of infection before
day + 28, similarly to negative controls. Of the six mice treated with compound 6a, on
day + 4, only one showed patent parasitaemia, while the remaining five mice remained
slide negative. On day + 7, all the compound 6a-treated mice became patent but with
significantly (p < 0.001) suppressed infection compared to negative controls; later on, all
the mice died of infection. Though compound 6b showed almost similar activity, four of
the treated mice survived until day + 28 albeit with up to 45 % parasitaemia; later on,
these mice also died of infection. On the other hand, all the mice treated with compound
7 survived beyond day + 28, again with up to 45 % parasitaemia and later died of infec-
tion. It is important to note here that all the mice treated with polymeric conjugates, com-
pared to negative-controls and the glucosamine conjugate, on day + 4, were either apa-
rasitemic or had significantly (p < 0.001) lower parasitaemia. Among polymeric conjugates,
compound 6b appeared to be the best with respect to suppression of parasitaemia. Never-
theless, all the mice treated with compound 7 survived beyond day + 28, which may be
explained on the basis of the infection-induced immunity that these mice would have
acquired due to the continued presence of infection for a relatively long period.
CONCLUSIONS
The prepared polymer-primaquine conjugates could be potentially useful antimala-
rial primaquine prodrugs of increased solubility and prolonged activity. Preliminary ex-
periments showed a significant blood-schizontocidal activity of PHEA-PQ and PHPA-
-PQ conjugates against parasitaemia induced in experimental animals. The polymeric co-
njugates showed better antimalarial activity than the glucosamine conjugate.
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Table I. Antimalarial evaluation of primaquine conjugates in vivo (parasite: Plasmodium berghei, host
animals: Swiss micea)
Conjugate Dose (mg kg–1)b
Parasitaemia (mean ± SD) on day (%)
day + 4 day + 7 day + 28
PQ-G (5) 150 0.2 ± 0.2 2.6 ± 1.0 all died
PHEA-PQ (6a) 75 0.02 ± 0.04 2.7 ± 1.1 all died
PHEA-PQ (6b) 150 0.1 ± 0.2 1.3 ± 0.6
2 died; 4 survived with
4050 % parastitaemia
PHPA-PQ (7) 150 0.2 ± 0.2 6.6 ± 1.8
all survived with
44 ± 6.54 % parasitaemia
Chloroquine
control
8 0 0
1 died; 5 survived
without infection
Vehicle control 0.5 mL per mouse 6.4 ± 1.7 19.6 ± 2.5 all diedc
a n = 6
b Drugging schedule: from day + 0 to day + 3.
c Average survival of untreated animals (vehicle control): 14 days.
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Acronyms and codes. – Bt – 1-benzotriazolyl; Btc – 1-benzotriazolylcarbonyl; DMF –
N,N’-dimethylformamide; IE – infected erythrocytes; MED – minimum effective dose;
NMR – nuclear magnetic resonance; PHEA – poly[a,b-(N-2-hydroxyethyl-DL-aspartami-
de)]; PHEA-PQ – poly[a,b-(N-2-hydroxyethyl-DL-aspartamide)]-primaquine conjugate;
PHPA – poly[a,b-(N-3-hydroxypropyl-DL-aspartamide)]; PHPA-PQ – poly[a,b-(N-3-hy-
droxypropyl-DL-aspartamide)]-primaquine conjugate; PQ – primaquine; PQ-Bt – prima-
quine benzotriazolide; PQ-G – primaquine-glucosamine conjugate; PSI – poly-DL-(2,5-
-dioxo-1,3-pyrrolidinediyl); TEA – triethylamine.
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S A @ E T A K
Makromolekulski prolijekovi. XII. Konjugati primakina:
Sinteza i preliminarno ispitivanje antimalarijskog djelovanja
ZRINKA RAJI], GABRIJELA KOS, BRANKA ZORC, PRATI PAL SINGH i SAVITA SINGH
U radu je opisana sinteza, karakterizacija i ispitivanje antimalarijskog djelovanja no-
vih konjugata primakina 5-7 s glukozaminom i dva polimera poliaspartamidnog tipa,
poli[a,b-(N-2-hidroksietil-DL-aspartamidom)] (PHEA) i poli[a,b-(N-3-hidroksipropil-DL-
-aspartamidom)] (PHPA). Konjugati su se razlikovali po vrsti kovalentne veze, duljini
razmaknice izme|u polimernog nosa~a i ljekovite tvari, molekulskoj masi i koli~ini ve-
zanog lijeka. [izontocidno djelovanje pripravljenih konjugata ispitano je na mi{evima in-
ficiranima parazitom Plasmodium berghei. Polimerni konjugati pokazali su ja~e antima-
larijsko djelovanje nego konjugat s glukozaminom.
Klju~ne rije~i: primakin, polimer-lijek konjugat, poliaspartamid, glukozamin, antimalarijsko djelovanje
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